DefinePK

DefinePK hosts the largest index of Pakistani journals, research articles, news headlines, and videos. It also offers chapter-level book search.

RANKL Signaling Pathway: A Potential Target for Antiresorptive Therapy in Rheumatoid Arthritis


Article Information

Title: RANKL Signaling Pathway: A Potential Target for Antiresorptive Therapy in Rheumatoid Arthritis

Authors: Sidrah Anjum, Attya Bhatti, Fahd Qadir, Usman Ashraf, Peter John

Journal: NUST Journal of Natural Sciences

HEC Recognition History
Category From To
Y 2024-10-01 2025-12-31
Y 2023-07-01 2024-09-30
Y 2022-07-01 2023-06-30
Y 2021-07-01 2022-06-30

Publisher: National University of Sciences & Technology, Rawalpindi/Islamabad (NUST)

Country: Pakistan

Year: 2015

Volume: 3

Issue: 1

Language: en

DOI: 10.53992/njns.v3i1.20

Keywords: Rheumatoid arthritisBone ResorptionRANK-RANKL signaling pathwayosteoclastogenesis

Categories

Abstract

Rheumatoid arthritis (RA) is a chronic polyarthritic autoimmune condition characterized by severe bone erosion. Osteoclasts, the bone resorbing cells, Rheumatoid arthritis (RA) is a chronic polyarthritic autoimmune condition characterized by severe bone erosion. Osteoclasts, the bone resorbing cells, are overly produced from the synovial inflammatory tissues in RA leading to excessive bone loss. RANKL-signaling pathway has been established to be the major pathway involved in osteoclastogenesis. This review highlights the role of around 40 osteoclastogenic factors involved in RANKL signaling and their potential to be targeted for antiresorptive therapy in RA. Furthermore, inhibitors of these proteins, which are already known to exhibit antiresorptive potential, have been reviewed. Elucidating new potential candidate therapeutic targets in the osteoclastogenesis pathway will open new avenues into the treatment and diagnosis of the arthritic conditionsare overly produced from the synovial inflammatory tissues in RA leading to excessive bone loss. RANKL-signaling pathway has been established to be the major pathway involved in osteoclastogenesis. This review highlights the role of around 40 osteoclastogenic factors involved in RANKL signaling and their potential to be targeted for antiresorptive therapy in RA. Furthermore, inhibitors of these proteins, which are already known to exhibit antiresorptive potential, have been reviewed. Elucidating new potential candidate therapeutic targets in the osteoclastogenesis pathway will open new avenues into the treatment and diagnosis of the arthritic conditions.


Paper summary is not available for this article yet.

Loading PDF...

Loading Statistics...